Correlation between Serum Tryptase, Mast Cells Positive to Tryptase and Microvascular Density in Colo-Rectal Cancer Patients: Possible Biological-Clinical Significance

Michele Ammendola¹,², Rosario Sacco¹, Giuseppe Sammarco¹, Giuseppe Donato³, Severino Montemurro², Eustachio Ruggieri², Rosa Patruno⁴, Ilaria Marelli⁵, Marica Cariello⁵, Angelo Vaccà⁶, Cosmo Damiano Gadaleta⁷, Girolamo Ranieri⁸

¹ Department of Medical and Surgery Science, Clinical Surgery Unit, University of Catanzaro “Magna Graecia” Medical School, Catanzaro, Italy, ² Surgery Unit, National Cancer Research Centre Istituto Tumori “Giovanni Paolo II”, Bari, Italy, ³ Department of Medical and Surgery Science, Pathology Unit, University of Catanzaro “Magna Graecia” Medical School, Catanzaro, Italy, ⁴ Department of Health, ASL BAT, Bari, Italy, ⁵ Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre Istituto Tumori “Giovanni Paolo II”, Bari, Italy, ⁶ Department of Biomedical Science and Human Oncology Clinica Medica “G. Baccelli”, University of Bari Medical School, Bari, Italy

Abstract

Background: Tryptase is a serine protease stored and released from mast cells (MCs) that plays a role in tumour angiogenesis. In this study we aimed to evaluate serum tryptase levels in colorectal cancer (CRC) patients before (STLBS) and after (STLAS) radical surgical resection. We also evaluated mast cell density positive to tryptase (MCDPT) and microvascular density (MVD) in primary tumour tissue.

Methods: A series of 61 patients with stage B and C CRC (according to the Astler and Coller staging system) were selected. Serum blood samples were collected from patients one day before and one day after surgery. Tryptase levels were measured using the UniCAP Tryptase Fluoroenzymeimmunoassay (Pharmacia, Uppsala, Sweden). Tumour sections were immunostained with a primary anti-tryptase antibody (clone AA1; Dako, Glostrup, Denmark) and an anti CD-34 antibody (QB-END 10; Bio-Optica Milan, Italy) by means of immunohistochemistry and then evaluated by image analysis methods.

Results: The mean ± s.d. STLBS and STLAS was 5.63±2.61 μg/L, and 3.39±1.47 μg/L respectively and a significant difference between mean levels was found: p = 0.000 by t-test. The mean ± s.d. of MCDPT and MVD was 8.13±3.28 and 29.16±7.39 respectively. A strong correlation between STLBS and MVD (r = 0.83, p = 0.000); STLBS and MCDPT (r = 0.60, p = 0.003); and MCDPT and MVD (r = 0.73; p = 0.001) was found.

Conclusion: Results demonstrated higher STLBS in CRC patients, indicating an involvement of MC tryptase in CRC angiogenesis. Data also indicated lower STLAS, suggesting the release of tryptase from tumour-infiltrating MCs. Serum tryptase levels may therefore play a role as a novel bio-marker predictive of response to radical surgery. In this context tryptase inhibitors such as Gabexate and Nafamostat Mesilate might be evaluated in adjuvant clinical trials as a new anti-angiogenic approach.

Introduction

Angiogenesis is a complex process involved in the growth, invasion, and metastasis of several human and animal tumours [1–3]. Mast Cells (MCs) intervene in this process releasing classical pro-angiogenic factors, such as vascular endothelial growth factor (VEGF), thymidine phosphorylase (TP), fibroblast growth factor-2 (FGF-2), and interleukin-6 (IL-6), as well as non-classical pro-angiogenic factors, such as tryptase, stored in their secretory granules [4–8]. Data from experimental tumour models suggest that MCs accumulate near to tumour cells before the onset of angiogenesis and that they are required for the macroscopic expansion and metastatic spread of primary tumour cells. Evidence for a specific role for MCs has been reported in animal and human cancers, such as MC tumours, head and neck, gastric, colorectal, lung and cutaneous malignancies, where MC density is highly correlated with the extent of tumour angiogenesis [9–19].

Tryptase is a neutral serine protease with a molecular weight of 134 kDa and a tetrameric structure consisting of non-covalently linked subunits. Four different forms of tryptase have been identified in human MCs thus far: α-, β-, γ- and δ-tryptase [20]. Of these, α- and β-tryptase are the two best circulating isoforms described. α-tryptase is constantly released from MCs in the bloodstream. β-tryptase is selectively concentrated in the secretory granules of MCs, and is constantly released into the bloodstream. Data from experimental tumour models suggest that tryptase is involved in several aspects of angiogenesis. Data also indicated lower STLAS, suggesting the release of tryptase from tumour-infiltrating MCs. Serum tryptase levels may therefore play a role as a novel bio-marker predictive of response to radical surgery. In this context tryptase inhibitors such as Gabexate and Nafamostat Mesilate might be evaluated in adjuvant clinical trials as a new anti-angiogenic approach.

Citation: Ammendola M, Sacco R, Sammarco G, Donato G, Montemurro S, et al. (2014) Correlation between Serum Tryptase, Mast Cells Positive to Tryptase and Microvascular Density in Colo-Rectal Cancer Patients: Possible Biological-Clinical Significance. PLoS ONE 9(6): e99512. doi:10.1371/journal.pone.0099512

Editor: Michael Muders, University Hospital Carl Gustav Carus Dresden, Germany

Received June 2, 2013; Accepted May 15, 2014; Published June 10, 2014

Copyright: © 2014 Ammendola et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors have no support or funding to report.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: giroran@tiscalinet.it
granules of MCs and is released only after degranulation. The presence of a high concentration of β-tryptase in the bloodstream is therefore a clear expression of MC activation [21–23]. Experimental studies have shown the release of tryptase from MCs to be a potent angiogenic stimulus which is able to induce neo-vascularization both in vitro and in vivo and is therefore involved in cancer development.

In this pilot study, we analyzed serum tryptase levels (STLs) in CRC patients before (STLBS) and after (STLAS) radical surgical resection; MC density positive to tryptase (MCDPT); and microvascular density (MVD) in primary tumour tissue in order to correlate each to the others and to evaluate STLs as a possible bio-marker predictive of response to radical surgery. In this context, the inhibition of tryptase by means of gabexate and nafamostat may be evaluated in adjuvant clinical trials as a new anti-cancer therapy [24–26].

Materials and Methods

Study Populations

A series of 61 CRC patients observed at the Clinical Surgery Unit of the “Magna Graecia” University of Catanzaro were selected. Helical computed tomography of the thorax, abdomen and pelvis revealed that no patients had distant metastases.

| Variable                             | Number of cases |
|--------------------------------------|-----------------|
| Overall series                       | 61              |
| Gender                               |                 |
| Male                                 | 37              |
| Female                               | 24              |
| Tumour site                          |                 |
| Colon                                | 43              |
| Rectal                               | 18              |
| Astler-Coller staging system         |                 |
| B                                    | 19              |
| C                                    | 42              |
| Histologic type                      |                 |
| Adenocarcinomas                      | 61              |
| Histologic grade                     |                 |
| G1-2                                 | 38              |
| G3                                   | 23              |

doi:10.1371/journal.pone.0099512.t001

Figure 1. Colon cancer sections immunostained for the evaluation of MCDPT and MVD at x400 magnification, high MCDPT and MVD respectively. In A a primary anti-tryptase antibody has been employed. Arrows indicate red mast cells positive to tryptase. In B a primary anti CD-34 antibody has been employed. Arrows indicate red positive microvessels.
doi:10.1371/journal.pone.0099512.g001

Figure 2. Colon cancer sections immunostained for the detail evaluation of MCDPT and MVD at x1000 magnification in oil respectively. In A a primary anti-tryptase antibody has been employed. The big arrows indicate single red mast cells positive to tryptase. The small arrow indicates the degranulation front of the mast cell forming a microvessel. In B a primary anti CD-34 antibody has been employed. The big arrow indicates a red positive microvessel. The small arrow indicates the nucleus of the endothelial cell. Note the lumen of the microvessel.
doi:10.1371/journal.pone.0099512.g002
Various surgical approaches were used: left and right open hemicolecotomy for colon cancer; open anterior resection, total meso-rectal excision and open abdomino-perineal resection for rectal cancer [27–30]. Patients with stage B and C CRC according to the Astler and Coller staging system were enrolled. In the global series there were 61 adenocarcinomas; the histopathological grading was performed according to the AJCC 7th Edition [31–32]. The clinico-pathological features of the patients are summarized in Table 1. Full ethical approval and signed consent from individual patients were obtained to conduct the study. The full name of ethics institutional review board that approved our study is: University Hospital Ethics Committee “Mater Domini”, Germaneto, Catanzaro, Italy.

Sample preparation
Blood samples were collected between 7:00 and 9:00 a.m. after overnight fasting, one day before and one day after surgical resection of the tumour. The samples were immediately dispensed into test tubes with serum separator tubes without additives (Becton Dickinson Vacutainer Systems Hemogard, Plymouth, UK) and left for at least 30 min at room temperature to allow for a complete clotting process. The samples were subsequently centrifuged at 1,500×g for 15 min at room temperature and the supernatant was recovered. Patient sera obtained were collected, aliquoted and frozen at −80°C until the analysis phase.

Prior to starting the analytical phase, the samples were thawed to room temperature and mixed thoroughly by vortexing at low speed in order to eliminate any residues of fibrin or other particulate matter potentially affecting reproducible results. Lipemic or hemolyzed samples potentially interfering with the assay were excluded from the analytical evaluation.

Serum tryptase levels were measured by fluoro enzyme-immunoassay (FEIA) for each sample, using Uni-CAP100 (Pharmacia Diagnostics AB, Uppsala, Sweden).

Figure 3. Adjacent normal mucosa section and colon cancer section immunostained for the evaluation of MCDPT and VEGF expression at x400 magnification respectively. In A a primary anti-tryptase antibody has been employed. Arrow indicates a single and unique red mast cells positive to tryptase in the observed field. In B a primary anti-VEGF antibody has been employed. Many red immunostained cancer cells. Big arrows indicate single red cytoplasmic cancer cells positive to VEGF.

Figure 4. Differences between STLBS (red line) and STLAS (blu line).

![Graph showing tryptase levels over a series of serum samples from patients](image-url)

Figure 4. Differences between STLBS (red line) and STLAS (blu line).

![Graph showing tryptase levels over a series of serum samples from patients](image-url)

**Figure 3.** Adjacent normal mucosa section and colon cancer section immunostained for the evaluation of MCDPT and VEGF expression at x400 magnification respectively. In A a primary anti-tryptase antibody has been employed. Arrow indicates a single and unique red mast cells positive to tryptase in the observed field. In B a primary anti-VEGF antibody has been employed. Many red immunostained cancer cells. Big arrows indicate single red cytoplasmic cancer cells positive to VEGF.

doi:10.1371/journal.pone.0099512.g003

**Figure 4.** Differences between STLBS (red line) and STLAS (blu line).

doi:10.1371/journal.pone.0099512.g004
Immunohistochemistry

For the evaluation of MCPT and MVD a three-layer biotin-avidin-peroxidase system was utilized [33]. Briefly, 4 μm-thick serial sections of formalin-fixed and paraffin-embedded tumour sample and adjacent normal mucosa were cut. Sections were then microwaved at 500 W for 10 min, after which endogenous peroxidise activity was blocked with 3% hydrogen peroxide solution. Tumour sections were incubated with an anti-tryptase (clone AA1; Dako, Glostrup, Denmark) diluted 1:100 for 1 h at room temperature and an anti-CD34 antibody (QB-END 10; Bio-Optica Milan, Italy) diluted 1:50 for 1 h at room temperature as a pan-endothelial marker respectively. Adjacent normal mucosa sections were incubated with an anti-tryptase (clone AA1; Dako, Glostrup, Denmark) and then processed in the above manner. Tumour sections were also incubated with an anti-VEGF (Clone VG-1) (Dako Glostrup, Denmark), diluted to 1:200 for 1 h at room temperature. The bound antibody was visualized using a biotinylated secondary antibody, avidin-biotin peroxidase complex.

Figure 5. Correlation analysis between MVD and STLBS.
doi:10.1371/journal.pone.0099512.g005

Figure 6. Correlation analysis between MCDPT and STLBS.
doi:10.1371/journal.pone.0099512.g006
and fast red. Nuclear counterstaining was performed with Gill’s haematoxylin no. 2 (Polysciences, Warrington, PA, USA). The primary antibody was omitted in negative controls.

Morphometrical assay

An image analysis system (Quantimet500 Leica, Wetzlar, Germany) was utilized [34]. In tumour sections five most immunostained areas (hot spots) were selected at low magnification and individual MCDPT (Fig. 1A) and MVD (Fig. 1B) were counted at x400 magnification (0.19 mm² area). The details were evaluated at x1000 magnification in oil (Figs. 2A and 2B respectively). In adjacent normal mucosa sections five most immunostained areas (hot spots) were selected at low magnification and individual MCDPT (Fig. 3A) were counted at x400 magnification (0.19 mm² area). In tumour tissue VEGF expression was evaluated (Fig 3B).

Statistical analysis

MCDPT and MVD mean values ± 1 standard deviations (SD) were evaluated by two independent observers (G.R. and G.D.) for each tumour sample and in all series of sections. MCDPT mean values ± 1 SD was also evaluated for each adjacent normal mucosa. Correlations between STLs, MCDPT, and MVD were calculated using Pearson’s (r) analysis. The correlations between the above indexes and the clinico-pathological features listed in Table 1 were analyzed by the Chi-square test. All statistical analyses were performed with the SPSS statistical software package (SPSS, Inc., Chicago, IL).

Results

The mean ± s.d. STLBS and STLAS were 5.63±2.61 µg/L and 3.39±1.47 µg/L respectively, and a significant difference between mean levels was found: p = 0.000 by t-test (Table 2, Fig. 4). In tumour tissue the mean ± s.d. of MCDPT and MVD was 8.13±3.28 and 29.16±7.39 respectively (Table 2). A significant correlation between STLBS and MVD (r = 0.83, p = 0.000, Fig. 5), STLBS and MCDPT (r = 0.60, p = 0.003, Fig. 6), and MCDPT and MVD (r = 0.73; p = 0.001, Fig. 7) was found. In adjacent normal mucosa the mean ± s.d. of MCDPT was 2.63±1.17 (Fig. 3A). A significant difference between tumour tissue MCDPT mean and adjacent normal mucosa MCDPT mean was found (p = 0.000). VEGF expression showed a strong cytoplasmic immunostaining in cancer tissue (Fig. 3B), however based to previously published data demonstrating a strong expression of VEGF in CRC tissue and blood fraction from patients as compared to adjacent normal mucosa and healthy controls respectively data were not shown [35–38].

No other significant correlations between the above indexes and the main clinico-pathological features listed in Table 1 was found.

Table 2. STLBS, STLAS, MCDPT and MVD means ± 1 standard deviations in a series of 61 colo-rectal cancer patients.

| STLBS µg/L | STLAS µg/L | MCDPT in Tumour Tissue | MVD in Tumour Tissue | MCDPT in Normal Mucosa |
|------------|------------|------------------------|----------------------|------------------------|
|            |            | X400 magnification (0.19 mm² area) | X400 Magnification (0.19 mm² area) | X400 magnification (0.19 mm² area) |
| 5.63±2.61* | 3.39±1.47* | 8.13±3.28* | 29.16±7.39* | 2.63±1.17* |

*Mean ± 1 standard deviation.

doi:10.1371/journal.pone.0099512.t002
Discussion

In this pilot study we have shown for the first time that STLBS strongly correlates with MCDPT and MVD in primary tumour tissue. Our data also demonstrates that STLs decrease following surgical resection in CRC patients with a significantly lower value of STLAS. Due to the release of tryptase from MC activation, we suggest that MCDPT in primary CRC tumour tissue represents the main source of serum tryptase. In our hypothesis, if primary tumour tissue is completely removed STLs should decrease in a day due to their approximately 4h long life-cycle. For these reasons, we detected STLs 24 h before surgery to evaluate their possible role as a circulating biomarker suggesting the presence of tumour tissue, and again 24 h after treatment to confirm the concentration decrease and, as a consequence, its possible implication of the absence of tumour tissue. We elaborate the background of our hypothesis based on previously published pilot data which suggested an increase of MCDPT in primary tumour tissue, and here our results also confirmed the reported data (Fig 1A, 3A). In these studies STLBS and MCDPT were correlated with MVD, suggesting their role in CRC angiogenesis. Our data agree with a previously published study that demonstrated an involvement of MCs in different malignancies such as hematological malignancies, melanoma, breast cancer, gastrointestinal and colo-rectal cancers, and also in animal tumour models.[38–43]. However the above studies did not focus on the changes in STLs before and after surgery, and no correlation between STLs, MCDPT and MVD was evaluated. Interestingly, tryptase released from MICS is involved in tumour angiogenesis by several mechanisms: firstly, tryptase stimulates the formation of vascular tubes in vitro and in vivo experimental models; secondly, tryptase is an agonist of the protease-activated receptor-2 in vascular endothelial cells that, in turn, induces angiogenesis [44]; thirdly, tryptase may stimulate the release of latent angiogenic factors bound to the extracellular matrix [45–47]. Considered together, the above data suggest that tryptase may be a potential surrogate bio-marker of tumour angiogenesis which is able to predict response to surgical treatment.

Therefore, with the primary source of tryptase production no longer existing, after 24 h a significant reduction in STLs should be expected. If elevated STLs persist after surgery, this would suggest that residual tumour tissue remains after surgical resection or, alternatively, that unknown metastases are present. In this context, several tryptase inhibitors such as Gabexate or Nafamostat mesilate may be evaluated in future clinical trials as a new anti-tumour and anti-angiogenic approach.

Acknowledgments

The authors would like to thank Caroline Oakley for manuscript editing.

Author Contributions

Conceived and designed the experiments: GR MA. Performed the experiments: GR RS GS DM ER RP IM MC AV. Analyzed the data: MA RP IM MC AV. Wrote the paper: MA RP IM MC AV CDG GR.

References

1. Ranieri G, Labriola A, Achille G, Florio G, Zito AF, et al. (2002) Microvessel density, mast cell density and thymidine phosphorylation expression in oral squamous carcinoma. Int J Oralol 21: 1317–1323.
2. Ranieri G, Ammendola M, Patruno R, Celano G, Zito FA, et al. (2009) Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oralol 35: 113–120.
3. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumour angiogenesis and metastasis correlation in invasive breast carcinoma. N Engl J Med 324: 1–8.
4. Kankiken JL, Hawkins IT, Naultakemini A (1997) Quantitative analysis of tryptase and chymase containing mast cells in benign and malignant breast lesions. Int J Cancer 72: 385–388.
5. Sowers H, Landor EL, Soto D, Schekors K, Swiggart LB, et al. (2007) Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced preinvasive endocrine tumours. Nat Med 13: 1211–1218.
6. Ribatti D, Ranieri G, Nico B, Benaginovsky V, Cirrilo E (2011) Tryptase and chymase are angiogenic in vivo in the choriocarcinoma chorioallantoic membrane assay. Int J Dev Biol 55: 99–102.
7. Mangia A, Malfettone A, Rossi R, Paradiso A, Ranieri G, et al. (2011) Tissue remodelling in breast cancer: human mast cells tryptase as an initiator of myofibroblast differentiation. Histopathology 58: 1096–1106.
8. Ranieri G, Gadadarlo-Caldarola G, Goffredo V, Patruno R, Mangia A, et al. (2012) Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development. Curr Med Chem 19: 938–944.
9. Ranieri G, Gadadarlo CD, Patruno R, Zizzo N, Daidone MG, et al. (2013) A model of study for human cancer: Spontaneous occurring tumors in dog. Biological features and translation for new anticancer therapies. Crit Rev Oncol Hematol 88: 187–197.
10. Ranieri G, Passantino L, Patruno R, Passantino G, Jimillo F, et al. (2003) The dog mast cell tumour as a model to study the relationship between angiogenesis, mast cell density and tumour malignancy. Oncol Rep 10: 1189–1193.
11. Igarashi M, Dhar DK, Kubota H, Yamamoto A, El-Assal O, et al. (1998) The prognostic significance of microvessel density and thymidine phosphorylation expression in squamous cell carcinoma of the esophagus. Cancer 82: 1225–1232.
12. Guhmbova M, Vlakyova T (2009) Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colon cancer. J Gastroenterol Hepatol 24: 1285–1273.
13. Yano H, Kinuta M, Tateishi H, Nakano Y, Matsui S, et al. (1999) Mast cell tryptase and angiogenesis in squamous cell carcinoma of the esophagus. Int J Clin Pathol 54: 940–947.
14. Ribatti D, Ranieri G, Nico B, Benaginovsky V, Cirrilo E (2011) Tryptase and chymase are angiogenic in vivo in the choriocarcinoma chorioallantoic membrane assay. Int J Dev Biol 55: 99–102.
15. Dethlefsen SM, Matsuura N, Zetter BR (1994) Mast cell accumulation at sites of murine tumor implantation: implications for angiogenesis and tumor metastasis. Int J Cancer 59: 395–401.
16. Patruno R, Arpaia N, Gadadarlo CD, Passantino L, Zizzo N, et al. (2009) VEGF concentration from plasma-activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model. J Cell Mol Med 13: 555–561.
17. Elpek GO, Gelen T, Akozy NH, Erosgan A, Dertsiz I, et al. (2001) The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the esophagus. J Clin Pathol 54: 940–944.
18. Kondo K, Muramatsu M, Okamoto Y, Jui D, Takai S, et al. (2006) Expression of chymase-positive cells in gastric cancer and its correlation with the angiogenesis. J Surg Oncol 93: 36–42.
19. Takahashi Y, Tsuchiya K, Naruke M (2000) Mast cell density is associated with angiogenesis and poor prognosis in palynoma adenocarcinoma. Cancer 80: 2686–2692.
20. Ch'ng S, Walls RA, Yuan I, Davis PF, Tan ST (2006) Mast cells and cutaneous malignancies. Mod Pathol 19: 149–159.
21. Hallgren J, Peijler G (2006) Biology of mast cell tryptase: an inflammatory mediator. J Biol Chem 281: 23417–23422.
22. Schwartz LB, Yunlinger JW, Miller J, Bokhari R, Dull D (1989) Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest 83: 1531–1555.
23. Bellone G, Silvestri S, Artusio E, Tibaoudi T, Turleini A, et al. (1997) Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-beta 1. J Cell Physiol 172: 1–11.
24. Bellone G, Carbone A, Sibona N, Bosco O, Tibaoudi T, et al. (2001) Aberrant activation of c-kit protects colon carcinoma cells against apoptosis and enhances their invasive potential. Cancer Res 61: 2200–2206.
25. Tommasen MG, Gruber BL (1997) Tryptase is a novel, potent angiogenic factor. J Clin Invest 99: 2691–2700.
26. Ribatti D, Ranieri G, Nico B, Benaginovsky V, Cirrilo E (2011) Tryptase and chymase are angiogenic in vivo in the choriocarcinoma chorioallantoic membrane assay. Int J Dev Biol 55: 99–102.
27. Attoe S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, et al. (2002) The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res 62: 4879–4883.
28. Nakashima M, Akiyoshi T, Ueno M, Fukunaga Y, Nagayama S, et al. (2011) Colon cancer in the splenic flexure: comparison of short-term outcomes of laparoscopic and open colectomy. Surg Laparosc Endosc Percutan Tech 21: 415–418.
29. Khan JS, Hermansdak AK, Flashman KG, Senapati A, O’Leary D, et al. (2011) Clinical outcome of laparoscopic and open colectomy for right colonic carcinoma. Ann R Coll Surg Eng 93: 603–607.
30. Garlipp B, Ptok H, Schmidt U, Stubs P, Scheidbach H, et al. (2012) Factors influencing the quality of total mesorectal excision. Br J Surg 99: 714–720.
31. Angenete E, Correa-Marinez A, Heath J, González E, Wedin A, et al. (2012) Ostomy function after abdominoperineal resection: a clinical and patient evaluation. Int J Colorectal Dis 27: 1267–1274.
32. Astler VB, Coller FA (1954) The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 139: 846–852.
33. Ratto C, Ricci (2011) Potential pitfalls concerning colorectal cancer classification in the seventh edition of the AJCC Cancer Staging Manual. Dis Colon Rectum 54: e232.
34. Ranieri G, Grammatica L, Patruno R, Zito AF, Valerio P, et al. (2007) A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients. J Cell Mol Med 11: 362–368.
35. Ranieri G, Achille G, Florio G, Labriola A, Marzullo F, et al. (2003) Biological-clinical significance of angiogenesis and mast cell infiltration in squamous cell carcinoma of the oral cavity. Acta Otorhinolaryngol Ital 21: 171–178.
36. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55: 3964–3968.
37. Ranieri G, Coviello M, Patruno R, Valerio P, Martino D, et al. (2004) Vascular endothelial growth factor concentrations in the plasma-activated platelets rich (P-APR) of healthy controls and colorectal cancer patients. Oncol Rep 11: 817–820.
38. Ranieri G, Coviello M, Chiriatti A, Stea B, Montemurro S, et al. (2004) Vascular endothelial growth factor assessment in different blood fractions of gastrointestinal cancer patients and healthy controls. Oncol Rep 11: 433–439.
39. Ribatti D, Vacc A, Nico B, Quondamatteo F, Ria R, et al. (1999) Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 79: 451–455.
40. Patruno R, March I, Zizzo N, Ammendola M, Nardulli P, et al. (2014) C-Kit Expression, Angiogenesis, and Grading in Canine Mast Cell Tumour: A Unique Model to Study C-Kit Driven Human Malignancies. BioMed Res Int 2014: ID 730246.
41. Ammendola M, Zuccalà V, Patruno R, Russo E, Luposella M, et al. (2013) Tryptase-positive mast cells and angiogenesis in keloids: a new possible postsurgical target for prevention. Updates Surg 65: 53–57.
42. Ammendola M, Sacco R, Donato G, Zuccalà V, Russo E, et al. (2013) Mast Cell positive to tryptase correlates with metastatic lymph nodes in gastrointestinal cancers patients surgically treated. Oncology 85: 111–116.
43. Ammendola M, Sacco R, Sammarco G, Donato G, Zuccalà V, et al. (2013) Mast cells positive to tryptase and c-Kit receptor expressing cells correlates with angiogenesis in gastric cancer patients surgically treated. Gastroenterol Res Pract 2013: ID 703163.
44. Liu Y, Mueller BM (2006) Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231cells via MAPK pathways. Biochem Biophys Res Commun 344: 1263–1270.
45. Nico B, Mangieri D, Crivellato E, Vacca A, Ribatti D (2008) Mast cells contribute to vasogenic mimicry in multiple myeloma. Stem Cells Dev 17: 19–22.
46. Hallegren J, Estrada S, Karlson U, Alving K, Pejler G (2001) Heparin antagonists are potent inhibitors of mast cell tryptase. Biochemistry 40: 7442–7459.
47. Fajardo I, Pejler G (2003) Human mast cell beta-tryptase is a gelatinase. J Immunol 171: 1492–1499.